Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 4/20 | 0.48 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18528997 | 1.00 | BCHE (0.48) | BCHESLC18A3HSP90AB1CHRM2CHRM4 | |
| SCHEMBL18528999 | 1.00 | BCHE (0.48) | BCHESLC18A3HSP90AB1CHRM2CHRM4 | |
| SCHEMBL28262599 | 0.87 | BCHE (0.55) | BCHECHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL26832050 | 0.82 | BCHE (0.51) | BCHECHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL13475155 | 0.82 | BCHE (0.51) | BCHECHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL30709622 | 0.82 | BCHE (0.51) | BCHECHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL22101386 | 0.81 | BCHE (0.50) | BCHECHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL22393926 | 0.81 | BCHE (0.50) | BCHECHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL22393637 | 0.81 | BCHE (0.50) | BCHECHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL20897888 | 0.80 | CHRM2 (0.50) | BCHESLC18A3HSP90AB1CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3337787-B1 | 1H-PYRAZOLO[3,4-B]PYRIDINE, 1H-THIENO[2,3-C]PYRAZOLE AND 1H-INDAZOLE CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS EXTRACELLULAR SIGNAL-REGULATED KINASES (ERK) INHIBITORS FOR TREATING CANCER | JS INNOPHARM SHANGHAI LTD (CN) | 2021-03-03 | — | — | EP | disclosed |
| EP-3337787-B1 | 1H-PYRAZOLO[3,4-B]PYRIDINE, 1H-THIENO[2,3-C]PYRAZOLE AND 1H-INDAZOLE CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS EXTRACELLULAR SIGNAL-REGULATED KINASES (ERK) INHIBITORS FOR TREATING CANCER | JS INNOPHARM SHANGHAI LTD (CN) | 2021-03-03 | — | — | EP | disclosed |
| US-10696687-B2 | Pyrazolo fused heterocyclic compounds as ERK inhibitors | CHANGZHOU JIEKAI PHARMATECH CO., LTD. (CN) | 2020-06-30 | — | — | US | disclosed |
| US-10696687-B2 | Pyrazolo fused heterocyclic compounds as ERK inhibitors | CHANGZHOU JIEKAI PHARMATECH CO., LTD. (CN) | 2020-06-30 | — | — | US | disclosed |
| US-20180237450-A1 | PYRAZOLO FUSED HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS | CHANGZHOU JIEKAI PHARMATECH CO., LTD. (CN) | 2018-08-23 | — | — | US | disclosed |
| EP-3337787-A1 | PYRAZOLO FUSED HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS | Changzhou Jiekai Pharmatech Co. Ltd. (CN) | 2018-06-27 | — | — | EP | disclosed |
| WO-2017028314-A1 | PYRAZOLO FUSED HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS | CHANGZHOU JIEKAI PHARMATECH CO., LTD. (CN) | 2017-02-23 | — | — | WO | disclosed |
| WO-2017028314-A1 | PYRAZOLO FUSED HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS | CHANGZHOU JIEKAI PHARMATECH CO., LTD. (CN) | 2017-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180237450-A1 | PYRAZOLO FUSED HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS | MAPK1, MAPK3, MAP3K20 | BCHE 4644/4885SLC18A3 2233/4885HSP90AB1 1257/4885 |
| US-10696687-B2 | Pyrazolo fused heterocyclic compounds as ERK inhibitors | MAPK1, MAPK3, MAP3K20 | BCHE 4644/4885SLC18A3 2233/4885HSP90AB1 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.